ITACITINIB ADIPATE

( DrugBank: Itacitinib, Adipate / KEGG DRUG: Itacitinib )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	2

告示番号	疾患名（ページ内リンク）	臨床試験数
228	閉塞性細気管支炎	1

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-004491-35-RO (EUCTR)	30/01/2020	18/03/2022	A study evaluating safety and efficacy of Itacitinib as treatment of moderate to severe ulcerative C ...	A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluat ...	Moderate to Severe Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;T ...	Product Name: Itacitinib Product Code: INCB039110 INN or Proposed INN: ITACITINIB ADIPATE Other descrip ...	Incyte Corporation	NULL	Not Recruiting			Female: yes Male: yes	206	Phase 2	United States;Czechia;Poland;Romania;Germany
2	EUCTR2018-004491-35-PL (EUCTR)	19/08/2019	03/07/2019	A study evaluating safety and efficacy of Itacitinib as treatment of moderate to severe ulcerative C ...	A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluat ...	Moderate to Severe Ulcerative Colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;T ...	Product Name: Itacitinib Product Code: INCB039110 INN or Proposed INN: ITACITINIB ADIPATE Other descrip ...	Incyte Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	206	Phase 2	United States;Czech Republic;Poland;Romania;Germany

臨床試験数 : 97 / 薬物数 : 118 - (DrugBank : 32) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 156

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04239989 (ClinicalTrials.gov)	April 8, 2021	30/12/2019	Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Tra ...	A Phase I Study to Assess Safety of Selective JAK 1 Inhibitor, Itacitinib, in Patients With Bronchio ...	Bronchiolitis Obliterans	Drug: Itacitinib;Drug: Itacitinib Adipate	M.D. Anderson Cancer Center	NULL	Recruiting	18 Years	75 Years	All	15	Phase 1	United States